Table 1: Broadly neutralizing monoclonal antibodies (bnMAbs) against HIV.

Epitope bnMAbDiscovery methodMedian or range of IC50 values (μg mL−1)References

MPER12F5EBV tfm23.8–7.8 [132][133]
4E10EBV tfm23.4 [134][88]
10E8, 7H6Neutralization assays60.3–1.5 [135][135]
Z13e1Phage display[57]

V1V23PG9Neutralization assays60.1–9.4 [134][89]
PG16Neutralization assays60.1–7.6 [136][89]
CH01–04EBV tfm2 0.02–4.9 (CH04) [137][137]
PGT141–145Neutralization assays60.2–2.1 [134][134]

V342G12EBV tfm22.4 [a][91]
PGT121–123Neutralization assays60.03–0.05 [134][134]
PGT125–131Neutralization assays60.02–0.5 [134][134]
PGT135–137Neutralization assays60.2–7.8 [134][134]
HGN194B cell immort100.1–3.7 [138][138]

CD4 bs5b12Phage display2.8 [134][92]
HJ16B cell immort100.01–9.8 [138][138]
VRC01–03RSC370.3 (VRC01 [134])[139]
NIH45-46gp120, 140 probes80.06–1.9 [140, 141][140]
3BNC55, 60, 62, 117gp120, 140 probes80.01–1.4 (BNC117 [141])[140]
12A12, 21, 30gp120, 140 probes80.08–2.6 (12A12 [141])[140]
VRC-PGV04, 4bRSC37, pyrosequencing90.2 (PGV04 [134])[139]
8ANC37, 131, 134gp120, 140 probes80.06–6.3 (131 [141])[140]
1B2530gp120, 140 probes80.06–9.8 [141][140]
1NC3, 7, 9gp120, 140 probes80.02–1.2 (INC9[141])[140]

Membrane-proximal external region of gp41.
2EBV transformation of B cells.
3V1V2 site on gp120.
4Glycan V3 site on gp120.
5CD4 binding site on GP120.
6Neutralization assays of B cells from infected donors.
7Resurfaced stabilized core 3 probe.
8Somatic mutation primers, gp120 and gp140 probes.
9454 pyrosequencing to characterize additional VRC01-like antibodies from HIV-1—infected individuals.
10Efficient B cell immortalization and high throughput screening.